Utah Medical Products, Inc. (UTMD) Leadership & Management Team Analysis
This article provides an analysis of Utah Medical Products, Inc. (UTMD)'s leadership, management, and recent company updates. It highlights key personnel information, board appointments, insider transactions, and dividend announcements, alongside earnings reports and analytical perspectives on the company's financial performance and risks. The content also touches on UTMD's market valuation, profitability, and legal challenges.
Brandes Investment Partners holds 14.12% of Utah Medical Products (NASDAQ: UTMD)
Brandes Investment Partners has filed an amended Schedule 13G, disclosing a beneficial ownership of 449,680 shares in Utah Medical Products (UTMD), which represents 14.12% of the company's class. The filing indicates that Brandes holds shared voting power over 412,007 of these shares, with the amendment signed by Glenn Carlson as Executive Director. This is a routine disclosure for large passive investors, signaling no immediate intent to influence control but providing transparency on significant holdings.
Utah Medical Products (NASDAQ: UTMD) Q1 2026 sales and profit decline
Utah Medical Products (UTMD) reported a decline in its Q1 2026 sales and profit compared to a strong prior year. Net sales decreased by 10.2% to $8,722k, primarily due to the loss of a major China distributor and an OEM customer, leading to a 14.4% drop in net income to $2,604k. Despite the revenue and earnings contraction, the company maintained strong gross margins and a robust balance sheet with significant cash reserves and no debt, continuing its share repurchase and dividend policy.
Utah Medical Products (Nasdaq:UTMD) - Stock Analysis
This report provides a stock analysis for Utah Medical Products (Nasdaq:UTMD), highlighting its current valuation, dividend performance, and recent financial updates. The company is trading 48.6% below its estimated fair value and offers a reliable dividend yield of 1.9%, well-covered by earnings and cash flows, despite a decline in earnings over the past five years. Recent news includes dividend declarations, annual general meetings, and quarterly earnings reports detailing revenue and EPS changes.
Number of shareholders of Utah Medical Products, Inc. – NASDAQ:UTMD
This article from TradingView provides information on Utah Medical Products, Inc. (UTMD) with a focus on financial data, specifically the number of shareholders. It appears to be an overview page for UTMD's financial metrics. The specific shareholder numbers are not directly in the provided text, but the structure indicates this section would contain such details.
Utah Medical Products To Go Ex-Dividend On June 17th, 2026 With 0.31 USD Dividend Per Share
Utah Medical Products announced it will go ex-dividend on June 17th, 2026, offering a dividend of $0.31 per share. Investors must own shares before this date to be eligible for the payment. This information is crucial for shareholders and potential investors tracking dividend payouts.
Utah Medical Products, Inc. announces Quarterly dividend, payable on July 03, 2026
Utah Medical Products, Inc. (UTMD) has announced a quarterly dividend of $0.3100 per share, payable on July 3, 2026. The ex-dividend date and record date for this payment are both set for June 17, 2026. The company specializes in producing medical devices for critical care areas and women's health.
Utah Medical Products raises quarterly dividend 1.6%
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share. This marks the third consecutive year of dividend increases for the company, maintaining dividend payments for 23 consecutive years. The dividend will be paid on July 3, 2026, to shareholders of record by June 17, 2026, with the company currently trading at a P/E ratio of 19 and appearing undervalued according to InvestingPro’s Fair Value analysis.
Utah Medical Products, Inc. Announces Quarterly Dividend
Utah Medical Products, Inc. (Nasdaq:UTMD) announced that its Board of Directors approved a quarterly cash dividend of thirty-one cents per share of common stock. This dividend is payable on July 3, 2026, to stockholders of record as of June 17, 2026. This represents a 1.6% increase over the dividend declared in the same quarter of the prior year.
Utah Medical raises quarterly dividend to $0.31 | UTMD Stock News
Utah Medical Products (NASDAQ: UTMD) has announced a quarterly cash dividend of $0.31 per share, payable on July 3, 2026, to shareholders of record as of June 17, 2026. This represents a 1.6% increase compared to the dividend declared in the same quarter last year. The company specializes in developing and marketing disposable and reusable medical devices for maternal and neonatal care globally.
Utah Medical Products raises quarterly dividend 1.6%
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share of common stock. This marks the third consecutive year of dividend increases for the company, which has maintained dividend payments for 23 years. The dividend will be paid on July 3, 2026, to stockholders of record by June 17, 2026.
Trading the Move, Not the Narrative: (UTMD) Edition
This article analyzes Utah Medical Products Inc. (NASDAQ: UTMD), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies resistance testing and suggests an exceptional short setup due to a favorable risk-reward ratio. The report details three AI-generated trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles.
Utah Medical Products, Inc. Declares Quarterly Dividend of $0.31 (NASDAQ:UTMD)
Utah Medical Products, Inc. (NASDAQ:UTMD) announced a quarterly dividend of $0.31 per share, to be paid on July 3rd to shareholders of record by June 17th. The dividend represents an annualized yield of 1.9%. The medical instruments supplier recently reported quarterly EPS of $0.82 on $8.72 million in revenue and has a market capitalization of $202.3 million.
Utah Medical (UTMD) investors approve directors, auditor and executive pay
Utah Medical Products, Inc. (UTMD) stockholders approved the election of Ernst G. Hoyer and James H. Beeson as directors, ratified Haynie & Co. as their independent public accounting firm for 2026, and, on an advisory basis, approved the compensation for executive officers at their annual meeting on May 1, 2026. The company intends to continue holding annual advisory votes on executive compensation. These decisions were formally reported in an 8-K filing.
Utah Medical Products (NASDAQ:UTMD) Shares Pass Above 200-Day Moving Average - Time to Sell?
Utah Medical Products (NASDAQ:UTMD) has seen its stock price cross above its 200-day moving average, trading as high as $65.68. The company reported quarterly earnings of $0.82 per share on revenue of $8.72 million and recently declared a quarterly dividend of $0.31 per share. Analysts generally rate the stock as "Hold," with institutional investors showing varied activity in their holdings.
Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs
Utah Medical Products (UTMD) reported an 11% decline in Q1 2026 earnings per share and a 10.2% drop in net sales year-over-year, underperforming the S&P 500. The decline was primarily attributed to the loss of sales from a former Chinese distributor and an OEM customer, alongside higher litigation costs and elevated operating expenses. Despite these challenges, the company maintained a strong balance sheet and indicated that full-year results are expected to align with previous projections.
Utah Medical Products (UTMD) Margin Compression Challenges Bullish Valuation Narratives Heading Into Q1 2026
Utah Medical Products (UTMD) is facing margin compression, with its net profit margin decreasing from 33.9% to 29.3% over the last year, alongside a 1.7% annual earnings decline over five years. Despite a seemingly attractive DCF fair value of US$116.24 compared to its current price of US$67.17, investors are challenged by slowing revenue growth and pressure on profitability. The company's 19x P/E ratio is above its peer average but below the industry, suggesting a cautious market sentiment due to its recent financial performance.
Utah Medical Products (UTMD) Q1 2026 Earnings: EPS $0.818, Revenue $8.72M -- Is It 12.5% Overvalued?
Utah Medical Products (UTMD) reported Q1 2026 earnings with diluted EPS of $0.818 and net sales of $8.72 million, marking a 10.2% year-over-year decline attributed to lost distributor and OEM volumes. Despite the sales drop, the company achieved gross margin expansion to 60.6% and maintains a strong, debt-free balance sheet with $87.41 million in cash, supported by ongoing share repurchases and dividends. GuruFocus values UTMD as 12.5% overvalued with a GF Score of 81/100, citing strong financial health and profitability but modest growth prospects.
Utah Medical Products (UTMD) Q1 2026 Earnings: EPS $0.818, Revenue $8.72M -- Is It 12.5% Overvalued?
Utah Medical Products (UTMD) reported a decline in Q1 2026 net sales and net income, largely due to the absence of sales to former distributors and OEM customers, which aligned with internal expectations. Despite the sales decline, the company achieved gross margin expansion and maintained a strong, debt-free balance sheet with significant cash and investments. UTMD's stock is currently considered 12.5% overvalued by GuruFocus, but its strong financial health and profitability indicators suggest a resilient company.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported earnings of $2.6 million, or 82 cents per share, in its first quarter. The medical device maker also announced revenue of $8.7 million for the period. This financial summary was generated using data from Zacks Investment Research.
Utah Medical Products (NASDAQ:UTMD) Issues Quarterly Earnings Results
Utah Medical Products (NASDAQ:UTMD) reported quarterly earnings per share of $0.82, with a net margin of 29.3% and a return on equity of 9.56%. The company also declared a quarterly dividend of $0.31 per share, leading to an annualized dividend of $1.24 and a yield of 1.8%. The stock traded at $70.69, reflecting a market cap of approximately $225 million and a P/E ratio of 20.31.
Double-digit revenue drop but strong margins at Utah Medical (Nasdaq: UTMD)
Utah Medical Products (UTMD) reported a significant decline in Q1 2026 revenue and net income, with net sales dropping 10.2% to $8.7 million and net income falling 14.4% to $2.6 million. This downturn was primarily attributed to the loss of key distribution and OEM relationships, specifically with a former China distributor and PendoTECH. Despite the revenue challenges, the company maintained strong profitability, with gross margin improving to 60.6%, and sustained a robust, debt-free balance sheet with increased cash and investments.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) announced its first-quarter earnings, reporting $2.6 million in net income. The medical device manufacturer posted a profit of 82 cents per share and generated $8.7 million in revenue for the quarter.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported its first-quarter earnings, detailing a profit of $2.6 million. The medical device maker achieved 82 cents profit per share and generated $8.7 million in revenue for the period.
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026
Utah Medical Products, Inc. (Nasdaq:UTMD) reported financial results for the first quarter of 2026, which were consistent with prior projections despite some declines compared to 1Q 2025. Key figures show a decrease in revenues, gross profit, operating income, net income, and EPS, largely attributed to the absence of sales to a former China distributor and an OEM customer. The company's balance sheet remains strong, with increased cash and investments, and continued share repurchases and dividend payments.
Utah Medical lost China sales in Q1, but gross margin rose to 60.6%
Utah Medical Products (UTMD) reported a decline in consolidated sales by 10.2% and EPS by 11.0% in Q1 2026, primarily due to lost sales to a former China distributor and PendoTECH. Despite lower revenues, the company's gross profit margin improved to 60.6%, and cash equivalents increased by $4.1 million year-over-year. The report highlights the company's mixed performance with earnings pressure offset by balance sheet strength and continued shareholder returns through dividends and share repurchases.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported first-quarter earnings of $2.6 million, translating to 82 cents per share. The medical device manufacturer also announced a revenue of $8.7 million for the period. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Utah Medical Products, Inc. Hits New 52-Week High at $69.01
Utah Medical Products, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week high of $69.01, a significant increase from its 52-week low of $51.26. The company boasts a market capitalization of USD 205 million, a P/E ratio of 18.00, and a remarkable dividend yield of 108.47%, despite its one-year performance of 1.94% lagging behind the S&P 500. With a debt-to-equity ratio of -0.71 and a return on equity of 9.46%, the company demonstrates a solid financial position.
Utah Medical Products, Inc. Experiences Revision in Stock Evaluation Amid Strong Financial Metrics
Utah Medical Products, Inc. has adjusted its stock valuation, now featuring a P/E ratio of 18 and an impressive dividend yield of 108.47%. The company has demonstrated strong financial performance, with a year-to-date return of 22.94%, significantly outperforming the S&P 500. These strong metrics and favorable comparisons to competitors highlight its competitive edge in the Pharmaceuticals & Biotechnology sector.
Utah Medical Products, Inc. Hits New 52-Week High at $69.55
Utah Medical Products, Inc. (UTMD) has reached a new 52-week high of $69.55, indicating strong performance within the pharmaceuticals and biotechnology sector. The microcap company, with a market capitalization of $205 million, has shown a 3.05% increase over the past year and boasts an impressive 108.47% dividend yield, alongside solid financial metrics like an 18.00 P/E ratio, 9.46% return on equity, and a 1.72 price-to-book ratio.
Utah Medical Products, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Utah Medical Products, Inc. has adjusted its valuation, with its stock currently priced at $64.53. The company boasts an 18 P/E ratio and a high dividend yield of 108.47%, although its annualized return of 20.39% trails the S&P 500. This evaluation highlights its competitive position within the Pharmaceuticals & Biotechnology sector, comparing its metrics against peers like Castle Biosciences and Tactile Systems Technology.
Utah Medical Products Faces Valuation Shift Amid Declining Financial Performance
Utah Medical Products, Inc. has seen its valuation grade shift from attractive to fair due to declining financial performance, despite some bullish technical indicators. The company reports a P/E ratio of 18, a price-to-book of 1.72, and positive ROE and ROCE, but has experienced declining operating profits over the last five years and negative results for the past five quarters. This signals potential concerns for investors despite its microcap status in the Pharmaceuticals & Biotechnology sector.
Total debt per share of Utah Medical Products, Inc. – SWB:UTM
This article focuses on the "Total debt per share" financial metric for Utah Medical Products, Inc. (SWB:UTM). It indicates the company's listing on the Stuttgart Stock Exchange and provides a general overview of its financial data within the context of health technology and medical specialties.
Price-Driven Insight from (UTMD) for Rule-Based Strategy
The article provides a price-driven insight for Utah Medical Products Inc. (NASDAQ: UTMD), highlighting a strong near-term sentiment with a long-term positive bias. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies: Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT), along with multi-timeframe signal analysis.
We Think You Can Look Beyond Utah Medical Products' (NASDAQ:UTMD) Lackluster Earnings
Utah Medical Products' (NASDAQ:UTMD) recent weak earnings are believed to be stronger than they appear due to a US$1.4m reduction from unusual, likely one-off, items. The article suggests that if these expenses do not recur, the company's profit is expected to increase, despite a recent fall in earnings per share. Investors are advised to look beyond these temporary factors and consider the company's underlying earnings potential.
Utah Medical Products Adjusts Valuation Grade Amidst Financial Challenges and Strong Metrics
Utah Medical Products, Inc. has seen its valuation grade shift from fair to attractive, despite recent financial challenges. The microcap company exhibits strong financial metrics such as a P/E ratio of 18, a price-to-book value of 1.72, and a high dividend yield of 108.47%, alongside a solid operational framework with a low debt-to-equity ratio and high institutional holdings. This reassessment occurs even as the company experienced a decline in profits, yet still delivered an 8.50% return over the past year.
Utah Medical Products, Inc. Experiences Revision in Its Stock Evaluation Amid Market Resilience
Utah Medical Products, Inc., a microcap company in pharmaceuticals and biotechnology, has adjusted its valuation, now showing a P/E ratio of 18 and a dividend yield of 108.47%. Its year-to-date return of 12.35% significantly outperforms the S&P 500, indicating resilience. Compared to peers, Utah Medical appears to be a more stable investment option.
Utah Medical Products' (NASDAQ:UTMD) Conservative Accounting Might Explain Soft Earnings
Utah Medical Products' recent lackluster earnings report, despite appearing soft, might be attributable to conservative accounting practices and negative unusual items totaling US$1.4m. These one-off deductions suggest that the company's statutory profit could be understating its true earnings potential. Consequently, analysts anticipate a potentially improved financial performance in the upcoming year if these unusual expenses do not recur.
Utah Medical Products' (NASDAQ:UTMD) Conservative Accounting Might Explain Soft Earnings
Utah Medical Products' recent earnings report, despite appearing lackluster, is likely influenced by conservative accounting practices, specifically a US$1.4 million reduction due to unusual one-off items. Stockholders seemed unconcerned, suggesting underlying positive factors. If these unusual expenses do not recur, the company's profit is expected to be higher next year, indicating that its statutory profit may currently understate its true earning potential.
[DEF 14A] UTAH MEDICAL PRODUCTS INC Definitive Proxy Statement
Utah Medical Products, Inc. (UTMD) has filed a Definitive Proxy Statement (DEF 14A) for its annual meeting on May 1, 2026. Stockholders will vote on re-electing two directors, ratifying Haynie & Company as the independent auditor, and an advisory vote on executive compensation. The document details compensation, stock ownership, corporate governance, and audit information, highlighting CEO pay, employee stock options, and the company's financial performance history compared to market indices.
(UTMD) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Utah Medical Products Inc. (NASDAQ: UTMD), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines several AI-generated trading strategies, including long, breakout, and short positions, along with risk management parameters. The analysis details support and resistance levels across different time horizons for informed trading decisions.
Top Analyst Reports for American Express, Intuitive Surgical & Shopify
Zacks Research Daily highlighted top analyst insights on 16 leading companies, focusing on American Express (AXP), Intuitive Surgical (ISRG), Shopify Inc. (SHOP), and Utah Medical Products, Inc. (UTMD). The reports detail each company's recent performance, growth drivers, and potential challenges, with American Express showing growth despite high costs, Intuitive Surgical excelling with its da Vinci system, and Shopify expanding its merchant base. The analysis also covers Utah Medical Products' strong balance sheet, along with brief mentions of other companies like Petróleo Brasileiro S.A. - Petrobras, Southern Copper Corp., and Agnico Eagle Mines Ltd.
UTMD PE Ratio & Valuation, Is UTMD Overvalued
Utah Medical Products Inc (UTMD) is currently in the Fair zone based on its forward PS ratio compared to its five-year average, suggesting it's fairly valued. The article details UTMD's Price-to-Book ratio, Free Cash Flow yield, and compares its P/S ratio to competitors, noting that its current P/S appears unsustainable given its revenue growth. The fair price of UTMD is calculated using a relative valuation method.
Utah Medical Products Stock: Steady Niche Player in Women's and Neonatal Healthcare with Reliable Di
Utah Medical Products (UTMD) is presented as a stable, niche player in the medical device sector, focusing on women's and neonatal healthcare. The company is valued by North American investors for its consistent dividend yield of around 2.2%, conservative growth profile, and resilience in a specialized market. Its financial stability, lean operations, and specialization in high-margin devices contribute to predictable cash flows, making it appealing for dividend-seeking and long-term investors.
Utah Medical Products Stock: Steady Niche Player in Women's and Neonatal Healthcare with Reliable Di
Utah Medical Products (NASDAQ: UTMD) is highlighted as a stable, niche player in the medical device sector, focusing on women's healthcare and neonatal care with consistent dividend appeal. The company's conservative growth profile, lean structure, and specialized product offerings contribute to its resilience and attraction for dividend-seeking investors. Its mid-cap status and low trading volume require cautious consideration for entry and exit but reward long-term holders.
UTAH MEDICAL PRODUCTS Cyclically Adjusted Book per Share: $3
This article from GuruFocus focuses on Utah Medical Products (UTMD) and its Cyclically Adjusted Book per Share, which was $32.42 as of September 2025. It explains the calculation of this metric, which averages the inflation-adjusted book value per share over the past 10 years, similar to Professor Robert Shiller's E10 concept. The article notes that UTMD has a GF Score of 81/100 and is considered "Fairly Valued" with 4 warning signs.
Utah Medical Products 2025 10-K: Revenue $38.5M, EPS $3.48
Utah Medical Products (UTMD) reported fiscal 2025 revenue of $38.52 million and diluted EPS of $3.48, a decrease from the previous year. The revenue decline was mainly due to lost OEM and China distributor orders, while EPS moderately benefited from share repurchases. Management anticipates stabilizing revenue in 2026 by securing new biopharma business and launching new products, with profitability expected to improve as amortization expenses ease after Q1.
Vanguard realignment leaves Utah Medical Products (UTMD) with 0% stake
The Vanguard Group has reported a 0% beneficial ownership stake in Utah Medical Products Inc. (UTMD) following an internal realignment effective January 12, 2026. This change, documented in an Amendment No. 2 to a Schedule 13G/A, signifies that Vanguard’s subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing clarifies that Vanguard no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.
Utah Medical Products, Inc. Experiences Revision in Its Stock Evaluation Metrics
Utah Medical Products, Inc. has adjusted its stock valuation, now featuring a P/E ratio of 18 and a price-to-book value of 1.72. The company exhibits a high dividend yield of 108.47%, along with strong returns on capital and equity. These metrics position Utah Medical Products favorably against competitors within the Pharmaceuticals & Biotechnology sector.
Utah Medical Products Adjusts Valuation Grade Amid Strong Financial Metrics and High Dividend Yield
Utah Medical Products, Inc. has received a more favorable valuation grade due to strong financial metrics. These include a competitive P/E ratio of 18, a reasonable Price to Book Value of 1.72, and a high dividend yield of 108.47%. Despite operational challenges and a decline in operating profit over the past five years, the company maintains a low debt-to-equity ratio and high institutional holdings.
